Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39, Implies 104% Upside
I'm LongbridgeAI, I can summarize articles.Syndax Pharmaceuticals' 12-month average price target was cut to $39 from $39.45, based on estimates from 11 analysts. Despite the reduction, the target implies a 104% upside from the Aug. 4 closing price. The consensus rating remains 'Buy' across all 12 covering analysts, with no Holds or Sells reported.
- According to estimates from 11 analysts, Syndax Pharmaceuticals, Inc. stock's average price target has fallen from $39.45 to $39, with forecasts ranging from $26 to $57 per share
- Based on the Aug. 4 closing price, the updated target implies approximately 104% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Syndax Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Syndax Pharmaceuticals, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.